The Cataract Backlog the World Forgot — and How It Gets Cleared
More than 100 million people are blind or visually impaired by a condition that a 12-minute operation can fix. The bottleneck was never the surgery. It is access, throughput, and the cost of a tray of consumables — and that is exactly where the map is being redrawn.
The 60-second brief
- Cataract is the single largest cause of avoidable blindness on Earth — and it is completely reversible with surgery.
- The backlog is concentrated in Africa, Latin America, South & Southeast Asia, the Caribbean and the Pacific — not because surgery is hard, but because volume and cost are.
- The high-volume model pioneered in India performs cataract surgery at world-class outcomes for a fraction of Western cost, largely by driving down the price of quality consumables.
- Ophthalmic solutions — viscoelastics (OVDs), capsule stains, intracameral antibiotics — are the quiet economic lever. Get them cheap and consistent, and a surgeon can double their weekly output.
- This is why hospitals and distributors across the Global South increasingly source their OVDs, trypan blue and IOLs from India.
A curable disease, left uncured for a hundred million people
Cataract — the clouding of the eye's natural lens — is responsible for roughly half of all blindness globally and a large share of moderate-to-severe visual impairment.[2][4] The tragedy is not the disease. The tragedy is that we have known how to cure it for decades. A cataract operation restores sight in minutes, and in high-volume settings the whole procedure — from incision to a folded lens sitting inside the eye — takes well under fifteen minutes.
So why do more than 100 million people still live in the fog?[1][3] Because a cure that exists is not the same as a cure that reaches you. The backlog sits almost entirely in low- and middle-income countries (LMICs), where the ratio of ophthalmologists to population can be one surgeon for every million people, where a patient may travel two days to reach an operating theatre, and where the cost of a single tray of surgical consumables can equal a week's wages.
Figures are drawn from WHO and the IAPB Vision Atlas, and from the Global Burden of Disease Vision Loss Expert Group's 2020 estimates[1][2][3][4] — presented as order-of-magnitude public-health estimates, not a clinical dataset. Country programmes report their own backlog numbers. Full sources are listed at the end of this article.
The backlog has a map — and these are its regions
The un-operated cataract population is not evenly spread. It clusters. Below is where the pressure is heaviest, and the countries within each region where demand for affordable, quality cataract supply is climbing fastest.
Sub-Saharan & North Africa
Nigeria · Kenya · Tanzania (incl. Dar es Salaam) · Uganda · Zimbabwe · Botswana · Rwanda · Senegal · Togo · Sudan · Somalia · Tunisia · Algeria
Africa carries one of the world's highest rates of cataract blindness relative to surgical capacity. Cataract Surgical Rates (CSR — surgeries per million per year) in much of the region sit far below the ~3,000+ needed to hold the backlog steady, let alone shrink it. Distances are vast, surgeon numbers thin, and outreach camps do the heavy lifting. What moves the needle here is predictable, low-cost consumable supply so that a visiting surgical team can operate on 40–60 eyes in a single camp day without running short of viscoelastic or stain.
Latin America & the Caribbean
Brazil · Peru · Bolivia · Paraguay · Uruguay · Honduras · Nicaragua · Panama · Costa Rica · Cuba · Dominican Republic · Guyana · Trinidad & Tobago · Bahamas
Latin America has strong pockets of surgical excellence sitting next to deep rural gaps. National "zero avoidable blindness" campaigns (several modelled on Cuba's and Brazil's programmes) have shown the region can clear backlog fast when consumables and IOLs are affordable and reliably stocked. The economics of the tray — OVD, stain, IOL — decides how many patients a public programme budget can reach in a year.
South & Southeast Asia
India · Vietnam · Philippines · Cambodia · Maldives · Timor-Leste · Mongolia · Sri Lanka region
This region is both the largest backlog and the birthplace of the solution. India runs some of the highest-throughput cataract services on Earth, proving that quality and volume are not opposites. Vietnam, the Philippines and Cambodia are scaling fast and increasingly source consumables and lenses from Indian manufacturers who can hit the price point without compromising sterility or optical quality.
Pacific, Central Asia & Eastern Europe edges
Samoa · Tonga · Solomon Islands · Mongolia · Lebanon · Serbia · Belarus
Small and remote health systems face a different problem: they cannot justify a large domestic supply chain, so every case depends on imported, shelf-stable consumables and IOLs. Reliable air-freighted supply of viscoelastics and lenses — with long shelf life and simple cold-chain-free storage — is what keeps a visiting surgical mission viable across scattered islands and thinly-served interiors.
MSICS: the surgery that unlocked the Global South
In wealthy countries, phacoemulsification ("phaco") is standard — an ultrasonic probe emulsifies the lens through a tiny incision. It is superb, but it depends on an expensive machine, consumable phaco tips, and steady power. In much of the world, the workhorse is Manual Small-Incision Cataract Surgery (MSICS) — a sutureless technique that, in randomised controlled trials, delivers visual outcomes comparable to phacoemulsification with a fraction of the capital cost and far greater resilience.[5][6]
MSICS is the reason a camp surgeon can restore sight to fifty people in a day. But MSICS still needs its consumables to be flawless: a capsule stain to see the anterior capsule in a dense white cataract, a viscoelastic to protect the corneal endothelium and maintain the chamber, and an intraocular lens to drop into the bag. Where an intracameral antibiotic is added at the close of surgery, large controlled studies have shown a substantial reduction in post-operative endophthalmitis — the rare but devastating infection every cataract programme fears.[7] The technique democratised the skill. Affordable, quality solutions democratise the throughput.
| Factor | Phaco | MSICS |
|---|---|---|
| Capital equipment | High (phaco machine) | Minimal |
| Cost per case | Higher | Lowest in class |
| Speed once skilled | Fast | Very fast, camp-scalable |
| Dense / mature cataracts | Challenging | Excellent |
| Power / infrastructure need | High | Low, resilient |
| Visual outcome (good hands) | Excellent | Comparable |
| Depends on quality OVD & stain | Yes | Yes — critically |
Technique choice is always the surgeon's clinical decision. The point is that both routes rest on the same small tray of consumables — and that tray's price is what scales, or throttles, a national programme.
The economics of a cataract tray
Strip a cataract operation down to what it consumes and you find a surprisingly short list. Get each item right — quality that a surgeon trusts, at a price a public programme can absorb — and the maths of clearing a national backlog suddenly works. Here is where the money in a single case actually goes, and why the "solutions" line dominates the conversation.
Relative, illustrative weighting of consumable cost — not a price list. Actual costs vary by market, procurement scale and lens type.
Why the OVD is the quiet hero
The ophthalmic viscoelastic device (OVD) is the most underrated line on the tray. It maintains the anterior chamber, protects the delicate corneal endothelium from surgical trauma, and creates the space to implant the lens safely. Two chemistries dominate: sodium hyaluronate (cohesive, superb chamber maintenance) and HPMC / hydroxypropyl methylcellulose (dispersive, excellent endothelial coating, and dramatically cheaper). In high-volume settings, a reliable HPMC or a well-purified hyaluronate is the difference between a programme that pencils out and one that doesn't.
Get the OVD wrong — inconsistent viscosity, particulate contamination, poor endothelial protection — and you pay for it downstream in corneal endothelial cell loss, corneal oedema, and slower recovery. Cheap-and-bad is the most expensive thing in the theatre. Cheap-and-good is the whole game.
The multiplier
Halve the consumable cost, and a fixed budget reaches 2× the patients.
That is the entire logic of high-volume eye care. Surgical skill is scalable through training. Machines are a one-time cost. But consumables recur on every single eye — so their price is the true throttle on how many people a country can un-blind this year.
How one country turned cataract surgery into an assembly line — without losing quality
India is the proof of concept the whole world now studies. Its highest-volume eye hospitals perform cataract surgery at a scale and cost that seemed impossible — hundreds of thousands of operations a year, world-benchmark complication rates, and a paying/non-paying cross-subsidy model that treats the poor for free.[8] The secret was never a single miracle. It was relentless standardisation of every step, and a domestic manufacturing base that drove the cost of viscoelastics, stains, IOLs and pharmaceuticals down to a level the rest of the Global South could finally afford.
That manufacturing base is why an ophthalmologist in Lagos, Lima, Hanoi or Suva can today order the same class of consumable a surgeon in Chennai uses — quality-controlled, batch-tested, and registered through each destination market's own regulatory pathway — at a landed cost that keeps a public programme solvent. The technology transfer of the 21st century in eye care is not a device. It is a supply chain.
For India: the awareness gap at home
Ironically, many Indian patients still don't know that the same quality of lens and solutions exported worldwide is available to them locally — and often assume "imported" means "better". It rarely does. A modern Indian-manufactured hydrophobic IOL, a purified sodium hyaluronate OVD and a properly formulated capsule stain meet the same optical and safety benchmarks the export market demands. Choosing well-made domestic solutions doesn't mean compromising outcomes; it means the same result at a price that lets more families say yes to surgery sooner. If you're a patient, the questions that matter are which lens fits your eye and life — not which country's flag is on the box.
The solutions behind the surgery
Agaaz Ophthalmics manufactures the consumables that make high-volume, high-quality cataract surgery economical — the viscoelastics, stains, intracameral agents and intraocular lenses that sit on the tray. Built for the realities of camp days and busy theatres: stable, shelf-friendly, batch-controlled, and priced for programmes that count every case.
Explore the full range on the Agaaz product portfolio — including foldable and specialty IOLs, fluorescein diagnostics and the wider surgical line.
References & peer-reviewed sources
Every headline claim in this article is anchored to primary public-health data or peer-reviewed clinical research. Follow the links to read the source.
- World Health Organization. World Report on Vision. Geneva: WHO, 2019. who.int
- International Agency for the Prevention of Blindness (IAPB). Vision Atlas — Global magnitude & causes of vision loss. iapb.org/learn/vision-atlas
- GBD 2019 Blindness & Vision Impairment Collaborators / Vision Loss Expert Group. Trends in prevalence of blindness and distance and near vision impairment over 30 years. Lancet Glob Health 2021;9(2):e130–e143. doi.org/10.1016/S2214-109X(20)30425-3
- GBD 2019 Blindness & Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years. Lancet Glob Health 2021;9(2):e144–e160. doi.org/10.1016/S2214-109X(20)30489-7
- Ruit S, Tabin G, Chang D, et al. A prospective randomized clinical trial of phacoemulsification vs manual sutureless small-incision extracapsular cataract surgery in Nepal. Am J Ophthalmol 2007;143(1):32–38. PubMed 17188040
- Gogate PM, Kulkarni SR, Krishnaiah S, et al. Safety and efficacy of phacoemulsification compared with manual small-incision cataract surgery by a randomized controlled clinical trial. Ophthalmology 2007;114(5):965–968. PubMed 17217857
- ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study. J Cataract Refract Surg 2007;33(6):978–988. PubMed 17321779
- Aravind Eye Care System. High-volume, high-quality cataract care & the cross-subsidy model. aravind.org
FAQ
Why is cataract blindness so much higher in developing countries if the surgery is simple?
What is MSICS and why is it preferred in high-volume settings?
What is an OVD and why does its quality matter so much?
Is Indian-manufactured ophthalmic supply as good as Western brands?
How does lowering consumable cost actually clear a national backlog?
How can a hospital or distributor in Africa, Latin America or Southeast Asia source Agaaz products?
Clearing the backlog is a supply-chain problem. We build the supply.
Surgeons, hospitals and distributors across Africa, Latin America, Asia and the Pacific partner with Agaaz for viscoelastics, stains, intracameral agents and IOLs that keep high-volume programmes affordable — without compromising the eye.
The Cataract Backlog the World Forgot — and How It Gets Cleared
More than 100 million people are blind or visually impaired by a condition that a 12-minute operation can fix. The bottleneck was never the surgery. It is access, throughput, and the cost of a tray of consumables — and that is exactly where the map is being redrawn.
The 60-second brief
- Cataract is the single largest cause of avoidable blindness on Earth — and it is completely reversible with surgery.
- The backlog is concentrated in Africa, Latin America, South & Southeast Asia, the Caribbean and the Pacific — not because surgery is hard, but because volume and cost are.
- The high-volume model pioneered in India performs cataract surgery at world-class outcomes for a fraction of Western cost, largely by driving down the price of quality consumables.
- Ophthalmic solutions — viscoelastics (OVDs), capsule stains, intracameral antibiotics — are the quiet economic lever. Get them cheap and consistent, and a surgeon can double their weekly output.
- This is why hospitals and distributors across the Global South increasingly source their OVDs, trypan blue and IOLs from India.
A curable disease, left uncured for a hundred million people
Cataract — the clouding of the eye's natural lens — is responsible for roughly half of all blindness globally and a large share of moderate-to-severe visual impairment.[2][4] The tragedy is not the disease. The tragedy is that we have known how to cure it for decades. A cataract operation restores sight in minutes, and in high-volume settings the whole procedure — from incision to a folded lens sitting inside the eye — takes well under fifteen minutes.
So why do more than 100 million people still live in the fog?[1][3] Because a cure that exists is not the same as a cure that reaches you. The backlog sits almost entirely in low- and middle-income countries (LMICs), where the ratio of ophthalmologists to population can be one surgeon for every million people, where a patient may travel two days to reach an operating theatre, and where the cost of a single tray of surgical consumables can equal a week's wages.
Figures are drawn from WHO and the IAPB Vision Atlas, and from the Global Burden of Disease Vision Loss Expert Group's 2020 estimates[1][2][3][4] — presented as order-of-magnitude public-health estimates, not a clinical dataset. Country programmes report their own backlog numbers. Full sources are listed at the end of this article.
The backlog has a map — and these are its regions
The un-operated cataract population is not evenly spread. It clusters. Below is where the pressure is heaviest, and the countries within each region where demand for affordable, quality cataract supply is climbing fastest.
Sub-Saharan & North Africa
Nigeria · Kenya · Tanzania (incl. Dar es Salaam) · Uganda · Zimbabwe · Botswana · Rwanda · Senegal · Togo · Sudan · Somalia · Tunisia · Algeria
Africa carries one of the world's highest rates of cataract blindness relative to surgical capacity. Cataract Surgical Rates (CSR — surgeries per million per year) in much of the region sit far below the ~3,000+ needed to hold the backlog steady, let alone shrink it. Distances are vast, surgeon numbers thin, and outreach camps do the heavy lifting. What moves the needle here is predictable, low-cost consumable supply so that a visiting surgical team can operate on 40–60 eyes in a single camp day without running short of viscoelastic or stain.
Latin America & the Caribbean
Brazil · Peru · Bolivia · Paraguay · Uruguay · Honduras · Nicaragua · Panama · Costa Rica · Cuba · Dominican Republic · Guyana · Trinidad & Tobago · Bahamas
Latin America has strong pockets of surgical excellence sitting next to deep rural gaps. National "zero avoidable blindness" campaigns (several modelled on Cuba's and Brazil's programmes) have shown the region can clear backlog fast when consumables and IOLs are affordable and reliably stocked. The economics of the tray — OVD, stain, IOL — decides how many patients a public programme budget can reach in a year.
South & Southeast Asia
India · Vietnam · Philippines · Cambodia · Maldives · Timor-Leste · Mongolia · Sri Lanka region
This region is both the largest backlog and the birthplace of the solution. India runs some of the highest-throughput cataract services on Earth, proving that quality and volume are not opposites. Vietnam, the Philippines and Cambodia are scaling fast and increasingly source consumables and lenses from Indian manufacturers who can hit the price point without compromising sterility or optical quality.
Pacific, Central Asia & Eastern Europe edges
Samoa · Tonga · Solomon Islands · Mongolia · Lebanon · Serbia · Belarus
Small and remote health systems face a different problem: they cannot justify a large domestic supply chain, so every case depends on imported, shelf-stable consumables and IOLs. Reliable air-freighted supply of viscoelastics and lenses — with long shelf life and simple cold-chain-free storage — is what keeps a visiting surgical mission viable across scattered islands and thinly-served interiors.
MSICS: the surgery that unlocked the Global South
In wealthy countries, phacoemulsification ("phaco") is standard — an ultrasonic probe emulsifies the lens through a tiny incision. It is superb, but it depends on an expensive machine, consumable phaco tips, and steady power. In much of the world, the workhorse is Manual Small-Incision Cataract Surgery (MSICS) — a sutureless technique that, in randomised controlled trials, delivers visual outcomes comparable to phacoemulsification with a fraction of the capital cost and far greater resilience.[5][6]
MSICS is the reason a camp surgeon can restore sight to fifty people in a day. But MSICS still needs its consumables to be flawless: a capsule stain to see the anterior capsule in a dense white cataract, a viscoelastic to protect the corneal endothelium and maintain the chamber, and an intraocular lens to drop into the bag. Where an intracameral antibiotic is added at the close of surgery, large controlled studies have shown a substantial reduction in post-operative endophthalmitis — the rare but devastating infection every cataract programme fears.[7] The technique democratised the skill. Affordable, quality solutions democratise the throughput.
| Factor | Phaco | MSICS |
|---|---|---|
| Capital equipment | High (phaco machine) | Minimal |
| Cost per case | Higher | Lowest in class |
| Speed once skilled | Fast | Very fast, camp-scalable |
| Dense / mature cataracts | Challenging | Excellent |
| Power / infrastructure need | High | Low, resilient |
| Visual outcome (good hands) | Excellent | Comparable |
| Depends on quality OVD & stain | Yes | Yes — critically |
Technique choice is always the surgeon's clinical decision. The point is that both routes rest on the same small tray of consumables — and that tray's price is what scales, or throttles, a national programme.
The economics of a cataract tray
Strip a cataract operation down to what it consumes and you find a surprisingly short list. Get each item right — quality that a surgeon trusts, at a price a public programme can absorb — and the maths of clearing a national backlog suddenly works. Here is where the money in a single case actually goes, and why the "solutions" line dominates the conversation.
Relative, illustrative weighting of consumable cost — not a price list. Actual costs vary by market, procurement scale and lens type.
Why the OVD is the quiet hero
The ophthalmic viscoelastic device (OVD) is the most underrated line on the tray. It maintains the anterior chamber, protects the delicate corneal endothelium from surgical trauma, and creates the space to implant the lens safely. Two chemistries dominate: sodium hyaluronate (cohesive, superb chamber maintenance) and HPMC / hydroxypropyl methylcellulose (dispersive, excellent endothelial coating, and dramatically cheaper). In high-volume settings, a reliable HPMC or a well-purified hyaluronate is the difference between a programme that pencils out and one that doesn't.
Get the OVD wrong — inconsistent viscosity, particulate contamination, poor endothelial protection — and you pay for it downstream in corneal endothelial cell loss, corneal oedema, and slower recovery. Cheap-and-bad is the most expensive thing in the theatre. Cheap-and-good is the whole game.
The multiplier
Halve the consumable cost, and a fixed budget reaches 2× the patients.
That is the entire logic of high-volume eye care. Surgical skill is scalable through training. Machines are a one-time cost. But consumables recur on every single eye — so their price is the true throttle on how many people a country can un-blind this year.
How one country turned cataract surgery into an assembly line — without losing quality
India is the proof of concept the whole world now studies. Its highest-volume eye hospitals perform cataract surgery at a scale and cost that seemed impossible — hundreds of thousands of operations a year, world-benchmark complication rates, and a paying/non-paying cross-subsidy model that treats the poor for free.[8] The secret was never a single miracle. It was relentless standardisation of every step, and a domestic manufacturing base that drove the cost of viscoelastics, stains, IOLs and pharmaceuticals down to a level the rest of the Global South could finally afford.
That manufacturing base is why an ophthalmologist in Lagos, Lima, Hanoi or Suva can today order the same class of consumable a surgeon in Chennai uses — quality-controlled, batch-tested, and registered through each destination market's own regulatory pathway — at a landed cost that keeps a public programme solvent. The technology transfer of the 21st century in eye care is not a device. It is a supply chain.
For India: the awareness gap at home
Ironically, many Indian patients still don't know that the same quality of lens and solutions exported worldwide is available to them locally — and often assume "imported" means "better". It rarely does. A modern Indian-manufactured hydrophobic IOL, a purified sodium hyaluronate OVD and a properly formulated capsule stain meet the same optical and safety benchmarks the export market demands. Choosing well-made domestic solutions doesn't mean compromising outcomes; it means the same result at a price that lets more families say yes to surgery sooner. If you're a patient, the questions that matter are which lens fits your eye and life — not which country's flag is on the box.
The solutions behind the surgery
Agaaz Ophthalmics manufactures the consumables that make high-volume, high-quality cataract surgery economical — the viscoelastics, stains, intracameral agents and intraocular lenses that sit on the tray. Built for the realities of camp days and busy theatres: stable, shelf-friendly, batch-controlled, and priced for programmes that count every case.
Explore the full range on the Agaaz product portfolio — including foldable and specialty IOLs, fluorescein diagnostics and the wider surgical line.
References & peer-reviewed sources
Every headline claim in this article is anchored to primary public-health data or peer-reviewed clinical research. Follow the links to read the source.
- World Health Organization. World Report on Vision. Geneva: WHO, 2019. who.int
- International Agency for the Prevention of Blindness (IAPB). Vision Atlas — Global magnitude & causes of vision loss. iapb.org/learn/vision-atlas
- GBD 2019 Blindness & Vision Impairment Collaborators / Vision Loss Expert Group. Trends in prevalence of blindness and distance and near vision impairment over 30 years. Lancet Glob Health 2021;9(2):e130–e143. doi.org/10.1016/S2214-109X(20)30425-3
- GBD 2019 Blindness & Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years. Lancet Glob Health 2021;9(2):e144–e160. doi.org/10.1016/S2214-109X(20)30489-7
- Ruit S, Tabin G, Chang D, et al. A prospective randomized clinical trial of phacoemulsification vs manual sutureless small-incision extracapsular cataract surgery in Nepal. Am J Ophthalmol 2007;143(1):32–38. PubMed 17188040
- Gogate PM, Kulkarni SR, Krishnaiah S, et al. Safety and efficacy of phacoemulsification compared with manual small-incision cataract surgery by a randomized controlled clinical trial. Ophthalmology 2007;114(5):965–968. PubMed 17217857
- ESCRS Endophthalmitis Study Group. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study. J Cataract Refract Surg 2007;33(6):978–988. PubMed 17321779
- Aravind Eye Care System. High-volume, high-quality cataract care & the cross-subsidy model. aravind.org
FAQ
Why is cataract blindness so much higher in developing countries if the surgery is simple?
What is MSICS and why is it preferred in high-volume settings?
What is an OVD and why does its quality matter so much?
Is Indian-manufactured ophthalmic supply as good as Western brands?
How does lowering consumable cost actually clear a national backlog?
How can a hospital or distributor in Africa, Latin America or Southeast Asia source Agaaz products?
Clearing the backlog is a supply-chain problem. We build the supply.
Surgeons, hospitals and distributors across Africa, Latin America, Asia and the Pacific partner with Agaaz for viscoelastics, stains, intracameral agents and IOLs that keep high-volume programmes affordable — without compromising the eye.
Start writing here...
The Global Cataract Backlog: High-Volume Surgery, the Economics of Quality OVDs & Why the Global South Sources Indian Ophthalmic Solutions 2026